The medicine is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 in adults.
Cancer focused healthcare service provider HealthCare Global Enterprises Limited (HCG) on Monday said it has become a majority stakeholder in Suchirayu Healthcare Solutions with the acquisition of additional 60.9 per cent for an undisclosed sum.
With the transaction, HCG has increased its holding in Suchirayu from the existing 17.7 per cent to 78.6 per cent, the company said in a statement. Suchirayu owns a multi-specialty hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds. HCG has operated and maintained the hospital since August 2017 and had the right to increase its stake up to 80 per cent, the statement said.